Clinical Value of Paclitaxel-based Combination Chemotherapy in the Treatment of Advanced Breast Cancer
Objective To study the clinical value of paclitaxel-based combination chemotherapy in the treatment of advanced breast cancer.Methods A total of 52 patients with advanced breast cancer in Zaozhuang Chest Hospital(Zaozhuang Cancer Hospital)from October 2019 to September 2023 were selected as the study objects,and divided into two groups by random number table method,26 cases in each group.The control group was treated with cyclo-phosphamide and epirubicin,and the observation group was treated with combined chemotherapy based on paclitaxel.The therapeutic effect of the two groups was compared.Results In the control group,the total effective rate of the con-trol group was 53.85%,lower than 80.77%of the observation group,and the difference was statistically significant(χ2=4.282,P<0.05).The scores of quality of life and physical activity in the observation group were higher than the control group,and the differences were statistically significant(both P<0.05).The value of tumor markers in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).The total incidence of ad-verse reactions was compared in two groups,and the difference was not statistically significant(P>0.05).Conclusion Combined chemotherapy based on paclitaxel has a superior therapeutic effect on advanced breast cancer patients.
Breast cancerPaclitaxelCyclophosphamideEpirubicinCombination chemotherapy
NETL
NSTL
万方数据
